Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Century Therapeutics (IPSC) Return on Sales (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Return on Sales for 4 consecutive years, with 0.23% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Sales rose 3925.0% to 0.23% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.23%, a 4815.0% increase, with the full-year FY2024 number at 19.08%, up 4207.0% from a year prior.
  • Return on Sales was 0.23% for Q3 2025 at Century Therapeutics, down from 0.2% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.7% in Q1 2025 to a low of 336.27% in Q2 2023.
  • A 4-year average of 65.05% and a median of 32.82% in 2024 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: crashed -31408bps in 2023, then skyrocketed 29580bps in 2024.
  • Century Therapeutics' Return on Sales stood at 60.8% in 2022, then plummeted by -142bps to 147.01% in 2023, then surged by 94bps to 8.44% in 2024, then soared by 97bps to 0.23% in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Return on Sales are 0.23% (Q3 2025), 0.2% (Q2 2025), and 0.7% (Q1 2025).